Genetic Testing & Diagnostic Pitfalls in Neuromuscular Disease

Genetic testing has transformed the diagnostic approach to neuromuscular disorders, with several hundred genes now linked to hereditary neuropathies, myopathies, and motor neuron diseases. Advances in next-generation sequencing (NGS) have improved diagnostic yield from under 20% with targeted single-gene testing to 40–60% with comprehensive panels and whole exome sequencing (WES). Despite this progress, diagnostic pitfalls remain common across the neuromuscular spectrum — from misclassification of hereditary neuropathies as acquired immune-mediated conditions to delayed recognition of inclusion body myositis (IBM) or myasthenia gravis. A systematic approach to genetic testing, combined with awareness of common mimics and diagnostic traps, is essential for accurate diagnosis and avoidance of unnecessary or harmful treatments.

Bottom Line

  • Phenotype-first approach: Clinical presentation and electrodiagnostic findings should guide genetic test selection; begin with targeted testing when the phenotype is classic (e.g., PMP22 duplication for CMT1A) before proceeding to broader panels or WES
  • Diagnostic yield: Gene panels achieve ~35–50% diagnostic yield in neuromuscular disease; WES adds 10–15% incremental yield, and combined WES/WGS with RNA sequencing can reach 62% in specialized centers
  • Negative testing does not exclude genetic disease: Current sequencing technologies miss repeat expansions (DM1, DM2, FSHD, C9orf72), large deletions/duplications, deep intronic variants, and mitochondrial DNA mutations unless specifically tested
  • CIDP overdiagnosis: Up to 50% of patients carrying a CIDP diagnosis in referral centers may have an alternative explanation; hereditary neuropathies (CMT1) are a common mimic, distinguishable by uniform conduction slowing
  • IBM misdiagnosis: Median delay to diagnosis exceeds 5 years; up to 25% of IBM patients are initially misdiagnosed as polymyositis and exposed to unnecessary immunosuppression
  • ALS mimics: Multifocal motor neuropathy and Kennedy disease are treatable or slowly progressive conditions that can mimic ALS; genetic testing for AR repeat expansion (Kennedy) and anti-GM1 antibodies should be considered before confirming an ALS diagnosis
  • Genetic counseling: Pre-test and post-test counseling is essential given the complexity of variant interpretation, implications for family members, and the emotional impact of genetic diagnoses

When to Order Genetic Testing

Clinical Indications for Genetic Testing in Neuromuscular Disease

  • Suspected hereditary neuropathy: Chronic distal-predominant weakness with foot deformity (pes cavus, hammer toes), areflexia, and family history; electrodiagnostic features of uniform demyelination (CMT1) or chronic axonal loss (CMT2)
  • Muscular dystrophy phenotype: Elevated CK with proximal weakness, particularly in young males (Duchenne/Becker) or adults with limb-girdle pattern (LGMD); calf pseudohypertrophy, Gower sign
  • Congenital myopathy or early-onset weakness: Neonatal or infantile hypotonia, delayed motor milestones, facial weakness, ophthalmoplegia; structural changes on muscle biopsy (cores, rods, centronuclear)
  • Motor neuron disease with atypical features or family history: Pure lower motor neuron presentation, young onset, slow progression, sensory involvement, or first-degree relative with ALS; C9orf72 repeat expansion and SOD1 testing indicated
  • Metabolic myopathy: Episodic weakness, exercise intolerance, myoglobinuria, second-wind phenomenon; consider glycogen storage or fatty acid oxidation disorders
  • Repeat expansion disorders: Myotonic dystrophy (grip myotonia, cataracts, cardiac conduction disease), facioscapulohumeral dystrophy (FSHD — facial and scapular weakness), spinal muscular atrophy (SMA — symmetric proximal weakness with preserved cognition)
  • Chronic neuropathy refractory to treatment: Suspected CIDP not responding to immunotherapy should prompt re-evaluation for hereditary causes

Types of Genetic Tests

Test Type Method Strengths Limitations
Targeted single-gene testing PCR, Sanger sequencing, MLPA Fast, inexpensive; ideal when phenotype is classic Tests only one gene; misses unexpected diagnoses
Gene panels (NGS) Targeted capture + NGS of 50–500 genes High coverage; 35–50% diagnostic yield; detects SNVs and small indels Misses repeat expansions, large structural variants; requires panel updates
Whole exome sequencing (WES) Capture + NGS of all coding regions (~20,000 genes) Detects novel variants; 40–60% yield with trio analysis Misses noncoding, intronic, repeat expansions, and large CNVs; high VUS rate
Whole genome sequencing (WGS) Sequencing of entire genome including noncoding regions Detects structural variants, intronic mutations, CNVs Costly; large data burden; interpretation challenges
Trinucleotide repeat analysis Repeat-primed PCR, Southern blot Required for DM1 (DMPK), DM2 (CNBP), C9orf72, SCA, Friedreich ataxia Specific to known repeat loci; not captured by standard NGS
MLPA (Multiplex Ligation-dependent Probe Amplification) Quantitative copy number analysis Detects deletions/duplications (PMP22, SMN1, dystrophin) Limited to targeted regions; does not detect point mutations
Methylation analysis Southern blot, methylation-sensitive restriction enzymes Essential for FSHD1 (D4Z4 repeat contraction on permissive 4qA haplotype) Technically demanding; FSHD2 requires separate SMCHD1 sequencing
Mitochondrial DNA sequencing NGS of mitochondrial genome; heteroplasmy quantification Detects mtDNA point mutations and deletions; important for mitochondrial myopathy Nuclear-encoded mitochondrial genes require WES; heteroplasmy varies by tissue

Genetic Testing Strategy by Condition

Condition First-Line Test Second-Line Test Key Notes
CMT (demyelinating) PMP22 duplication/deletion (MLPA) GJB1, MPZ, then CMT gene panel PMP22 duplication accounts for 55% of genetically confirmed CMT; uniform slowing <38 m/s in upper limbs
CMT (axonal) CMT gene panel WES (yield only ~20% for axonal CMT) MFN2 is the most common cause (7–12%); over 30 known CMT2 genes
SMA SMN1 deletion/copy number (MLPA or qPCR) SMN1 sequencing if single deletion (compound heterozygote) Homozygous SMN1 deletion in ~95% of SMA; SMN2 copy number determines severity and treatment eligibility
Duchenne/Becker MD Dystrophin gene (DMD) deletion/duplication (MLPA) DMD sequencing for point mutations ~65% large deletions, ~10% duplications, ~25% point mutations; reading frame rule predicts severity
LGMD LGMD gene panel (30–40 genes) WES with trio analysis 2023 expert consensus recommends comprehensive panel; protein testing on biopsy can guide genetics
Myotonic dystrophy type 1 DMPK CTG repeat analysis (repeat-primed PCR) Southern blot for large expansions Anticipation with maternal transmission; >50 repeats diagnostic; standard NGS cannot detect
Myotonic dystrophy type 2 CNBP CCTG repeat analysis — No anticipation; often milder; proximal weakness predominant
FSHD D4Z4 repeat contraction + 4qA haplotype (molecular combing or Southern blot) SMCHD1 sequencing (FSHD2) FSHD1 (~95%): D4Z4 contraction 1–10 repeats on permissive allele; FSHD2: SMCHD1 + moderate contraction
ALS (familial or atypical) C9orf72 repeat expansion + SOD1 sequencing ALS gene panel (FUS, TARDBP, TBK1, others) C9orf72 repeat in ~40% of familial ALS and ~7% of sporadic ALS; requires repeat-primed PCR
Hereditary TTR amyloidosis TTR gene sequencing — Val30Met most common worldwide; multiple disease-modifying therapies available (tafamidis, patisiran, vutrisiran, inotersen)
Congenital myasthenic syndromes CMS gene panel (CHRNE, RAPSN, DOK7, COLQ, others) WES Seronegative MG phenotype in childhood; response to pyridostigmine or 3,4-DAP may vary by subtype

Interpreting Genetic Test Results

ACMG Variant Classification

The American College of Medical Genetics and Genomics (ACMG) classifies variants into five categories that determine clinical actionability. Understanding these categories is critical for appropriate patient counseling and management decisions.

Classification Definition Clinical Action
Pathogenic Strong evidence of disease causation (functional studies, segregation, population data) Confirms diagnosis; guides treatment and family screening
Likely pathogenic ≥90% probability of being disease-causing Generally treated as pathogenic for clinical decision-making
Variant of uncertain significance (VUS) Insufficient evidence to classify as pathogenic or benign Should NOT be used for clinical decisions; may be reclassified over time; segregation studies in family members can help
Likely benign ≥90% probability of being non-pathogenic Generally not reported or acted upon clinically
Benign Strong evidence against disease causation No clinical significance

Key Principles in Variant Interpretation

  • A negative result does not exclude genetic disease: Current testing misses ~40% of hereditary neuromuscular disorders; consider WES reanalysis (new gene discoveries), RNA sequencing, or WGS if initial testing is negative and clinical suspicion remains high
  • VUS management: Do not alter treatment based on a VUS; periodic reanalysis every 2–3 years may lead to reclassification as new evidence emerges; family segregation studies can upgrade or downgrade a VUS
  • Trio analysis improves yield: Sequencing both parents alongside the proband increases diagnostic yield by 10–15% by enabling de novo variant detection and phase determination for recessive conditions
  • Cascade testing: Once a pathogenic variant is identified, targeted testing of at-risk family members is efficient, inexpensive, and critical for genetic counseling and reproductive planning
  • Genetic counseling is essential: Pre-test counseling should address the possibility of uncertain results, incidental findings, and implications for insurance; post-test counseling should interpret results in clinical context

Common Diagnostic Pitfalls in Neuromuscular Disease

CMT Misdiagnosed as CIDP

CIDP Overdiagnosis in Hereditary Neuropathy

  • A multicenter retrospective study found that 3.2% of patients diagnosed with CIDP actually had genetically confirmed CMT
  • Referral center studies show up to 50% of patients carrying a CIDP diagnosis may have an alternative explanation for their neuropathy
  • Key electrodiagnostic clue: CMT1 shows uniform slowing of motor conduction velocities across all nerves (typically ~20 m/s in CMT1A), whereas CIDP produces non-uniform slowing with conduction block and temporal dispersion
  • Red flags for CMT over CIDP: Childhood or adolescent onset, pes cavus and hammer toes, family history of neuropathy, absence of response to immunotherapy, and prominent distal atrophy disproportionate to weakness duration
  • Exception: Some CMT subtypes (GJB1/CMTX1, FIG4/CMT4J) can show features of acquired demyelination including conduction block, complicating distinction

Inclusion Body Myositis Misdiagnosed as Polymyositis

IBM Diagnostic Delay

  • Median time to accurate IBM diagnosis exceeds 5 years; up to 25% of patients are initially misdiagnosed as polymyositis
  • Key distinguishing features of IBM: Asymmetric weakness, early finger flexor and quadriceps involvement (not typical proximal-only pattern), poor response to immunosuppression, age >45 years
  • Biopsy pitfall: Rimmed vacuoles and congophilic inclusions are the hallmark pathologic findings but may be absent in up to 25% of biopsies, leading to an erroneous diagnosis of “polymyositis”
  • Serologic clue: Anti-cN1A (cytosolic 5′-nucleotidase 1A) antibodies are present in 33–76% of IBM patients and support the diagnosis when biopsy is inconclusive
  • Consequence of misdiagnosis: Patients receive prolonged immunosuppressive therapy (steroids, methotrexate, IVIG) without benefit while experiencing progressive functional decline

Myasthenia Gravis Misdiagnosed as Functional Disorder

Delayed Recognition of MG

  • Fluctuating, fatigable weakness — worse with activity and better with rest — can be misattributed to anxiety, depression, or functional neurological disorder
  • Seronegative MG: Up to 10–15% of generalized MG patients are AChR and MuSK antibody-negative, increasing diagnostic difficulty; low-density lipoprotein receptor-related protein 4 (LRP4) antibodies may be present in a subset
  • Ocular MG pitfall: Isolated ptosis and diplopia may be dismissed as age-related or attributed to other causes; ice pack test and repetitive nerve stimulation should be performed
  • In congenital myasthenic syndromes (CMS), seronegative childhood-onset MG should prompt genetic testing (CHRNE, DOK7, RAPSN, COLQ) as these patients do not respond to immunotherapy but may respond to pyridostigmine or 3,4-DAP

ALS Mimics

Treatable and Slowly Progressive ALS Mimics

  • Multifocal motor neuropathy (MMN): Pure motor, asymmetric weakness with conduction block on NCS; anti-GM1 IgM antibodies positive in ~50%; responds to IVIG — must be excluded before diagnosing ALS
  • Kennedy disease (SBMA): X-linked; bulbar involvement (dysphagia, dysarthria), proximal weakness, gynecomastia, reduced fertility, and sensory neuropathy on NCS; confirmed by CAG repeat expansion in the androgen receptor gene; slowly progressive with near-normal lifespan
  • Cervical spondylotic myelopathy: Can cause upper and lower motor neuron signs in the upper limbs with upper motor neuron signs in the lower limbs, closely mimicking ALS; MRI cervical spine is essential
  • Adult-onset SMA (SMA type 4): Slowly progressive pure lower motor neuron weakness; SMN1 testing required
  • Benign fasciculation syndrome: Fasciculations without progressive weakness, atrophy, or upper motor neuron signs; normal NCS/EMG or isolated fasciculation potentials; reassurance is the primary treatment

Medication-Related Diagnostic Pitfalls

Drug-Induced Myopathy Mimicking or Masking Primary Disease

  • Statin-induced immune-mediated necrotizing myopathy (anti-HMGCR): Unlike simple statin myalgia, this autoimmune condition persists and progresses after statin discontinuation; CK remains markedly elevated; anti-HMGCR antibodies are diagnostic; requires immunosuppressive treatment
  • Steroid myopathy complicating treated myositis: Proximal weakness that develops or worsens during corticosteroid therapy for inflammatory myopathy creates a clinical dilemma — is the disease flaring or is the treatment causing harm? CK trending, EMG findings (irritability in myositis vs. non-irritable in steroid myopathy), and MRI edema pattern can help differentiate
  • Thyroid myopathy: Both hypothyroidism and hyperthyroidism cause myopathy; TSH should be checked in all patients with unexplained proximal weakness or elevated CK; hypothyroid myopathy can mimic polymyositis with elevated CK up to 10× normal
  • Colchicine and chloroquine myopathy: Can cause vacuolar myopathy mimicking IBM or metabolic myopathy; drug history review is essential

Cost and Access Considerations

The cost of genetic testing varies widely depending on the test type and commercial laboratory. Single-gene tests typically range from $200–$500, while comprehensive gene panels cost $1,000–$3,000 and WES/WGS range from $3,000–$7,000. Insurance coverage has expanded significantly, with most major payers covering genetic testing when clinical criteria are met (documented clinical findings, family history, or non-diagnostic conventional workup). Prior authorization is often required.

Practical Access Strategies

  • Commercial laboratories: Invitae, GeneDx, Prevention Genetics, and Blueprint Genetics offer comprehensive neuromuscular panels with financial assistance programs for uninsured or underinsured patients
  • Research programs: The Inherited Neuropathies Consortium (INC) and the Undiagnosed Diseases Program (UDP) at the NIH offer no-cost genetic testing for qualifying patients
  • Tiered approach reduces cost: Starting with targeted testing when the phenotype is classic (e.g., PMP22 MLPA for suspected CMT1A at ~$300) avoids unnecessary expense; broader panels and WES are reserved for inconclusive cases
  • Re-analysis: Requesting periodic re-analysis of existing WES data (every 2–3 years) can identify newly discovered gene associations at minimal additional cost
  • Turnaround time: Single-gene tests return in 1–2 weeks; panels in 4–8 weeks; WES in 8–16 weeks; urgent clinical scenarios (e.g., SMA in infants for treatment eligibility) may qualify for expedited processing

References

  1. Saporta ASD, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011;69(1):22–33.
  2. Cortese A, Wilcox JE, Polke JM, et al. Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease. Neurology. 2020;94(1):e51–e61.
  3. Hauw F, Fargeot G, Adams D, et al. Charcot-Marie-Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: an international multicentric retrospective study. Eur J Neurol. 2021;28(9):2846–2854.
  4. Broers MC, Bunschoten C, Nieboer D, et al. Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2021;28(4):1065–1073.
  5. Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study. J Neurol Neurosurg Psychiatry. 2015;86(8):873–878.
  6. Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020;52(5):473–481.
  7. Oza AM, DiStefano MT, Hemphill SE, et al. Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss. Hum Mutat. 2018;39(11):1593–1613.
  8. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP. Genet Med. 2015;17(5):405–424.
  9. Beecroft SJ, Yau KS, Allcock RJN, et al. Targeted gene panel use in 2249 neuromuscular patients: the Australasian referral center experience. Ann Clin Transl Neurol. 2020;7(3):353–362.
  10. Neurology Expert Consensus. Expert consensus on genetic diagnostic approaches for patients with limb-girdle muscular dystrophy. Neurology. 2024;103(12):e214291.
  11. Gonzalez M, Falk MJ, Gai X, et al. Innovative genomic collaboration using the GENESIS platform. Hum Mutat. 2015;36(10):950–956.
  12. Westra D, Schouten MI, Stunnenberg BC, et al. Next-generation sequencing and comprehensive data reassessment in 263 adult patients with neuromuscular disorders. J Neurol. 2024;271(2):789–800.
  13. Cummings BB, Marshall JL, Tukiainen T, et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med. 2017;9(386):eaal5209.
  14. Berger A, Schossig A, Baets J, et al. Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone. Brain. 2024;147(7):2415–2427.
  15. Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257–272.
  16. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176–3184.
  17. Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016;75(4):696–701.
  18. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374(7):664–669.
  19. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force. Eur J Neurol. 2021;28(11):3556–3583.
  20. Fernandes Filho JA, Gerhardt GH. Kennedy disease: clinical significance of X-linked recessive inheritance. Neurology. 2008;71(18):1441.